EU approves Boston Sci's stent with different polymer

Editorial Staff | | Cardiovascular Business | Interventional Cardiology

Boston Scientific has received CE Mark approval for its Synergy everolimus-eluting platinum chromium coronary stent system featuring an abluminal (outer) bioabsorbable polymer coating.

The Synergy stent has a proprietary PLGA polymer and everolimus-drug coating that dissipate in three months, according to the Natick, Mass.-based company, which added the absorption of the coating is the result of seven years of research and development.

The clinical program supporting Synergy builds on the EVOLVE six-month study results, which demonstrated non-inferiority to Boston Scientific's Promus Element stent for the primary angiographic endpoint of in-stent late loss. A pivotal trial, EVOLVE II, has been designed to support FDA and Japanese Ministry of Health, Labor and Welfare approval of Synergy and is expected to begin enrollment later this year.  EVOLVE II is a global, multicenter, randomized, controlled, pivotal trial that will enroll 1,684 patients in 160 sites globally.

Synergy will be available in various sizes to select centers in Europe and other areas by early 2013. The company said this "limited market release" is expected to provide additional data to support the clinical and economic benefits of this bioabsorbable technology. A commercial launch of the Synergy is planned for early 2014.

The Synergy stent is an investigational device, not available for sale in the U.S. and Japan.

Editorial Staff

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."